Celgene obtained the FDA's approval to market Revlimid, or lenalidomide, in mantle cell lymphoma patients whose condition has relapsed or progressed after receiving two previous treatment regimens, one of which should include Takeda Pharmaceutical's Velcade, or bortezomib. The approval, based on the results of the MCL-001 midstage trial, makes Revlimid the first oral drug for MCL.
FDA expands use of Revlimid to include mantle cell lymphoma
SmartBrief Job Listings for Health Care
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Staff VP Medical Policy Development-81321||